Balyasny Asset Management LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

$58 Billion
Q3 2024

A detailed history of Balyasny Asset Management LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 101,852 shares of ARWR stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,852

Holding current value

$2.14 Million

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $1.97 Million - $3.01 Million	101,852 New	101,852 $1.97 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $6.4 Million - $10.4 Million	270,408 Added 5026.17%	275,788 $7.01 Million
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $4.77 Million - $6.91 Million	-170,303 Reduced 96.94%	5,380 $218,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $15,140 - $24,686	-511 Reduced 0.29%	175,683 $5.81 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $4.34 Million - $7.9 Million	156,013 Added 773.07%	176,194 $6.2 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $393,188 - $694,382	9,924 Added 96.75%	20,181 $928,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $5 Million - $7.1 Million	-86,013 Reduced 89.35%	10,257 $680,000
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $5.62 Million - $8.18 Million	96,270 New	96,270 $6.01 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $2.12 Million - $3.13 Million	-34,543 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $1.51 Million - $2.95 Million	34,543 New	34,543 $2.65 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $217,442 - $667,557	-10,576 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $297,608 - $772,153	10,576 New	10,576 $671,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.23B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Arrowhead Pharmaceuticals, Inc. Transaction History